In this edition of Psoriasis Prime Time, the faculty reviews the use of allosteric tyrosine kinase 2 (TYK2) inhibitors in the treatment of hard-to-treat psoriasis, including the rationale for TYK2 inhibition and clinical data associated with TYK2 inhibitors in psoriasis and emerging data in psoriatic arthritis (PsA). In addition, screening for PsA and use of systemic treatments to reduce joint symptoms are discussed.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/OIQGEN
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 63233.75 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest